Wells Fargo Rates Nuvalent (NUVL) hold, $124 Price Target

Analyst Eva Fortea Verdejo lowered the rating on the clinical-stage biotech firm to Hold with a $124.00 price target, a 0.61% upside from the current price.

By EarningsIQ Research Desk · Published Jun 14, 2026, 2:01 AM EDT · Updated Jun 15, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Wells Fargo rated Nuvalent, Inc. ($NUVL) "hold" with a $124 price target on June 9, 2026.

Since the rating, $NUVL is up 0.1% after 1 week and up 0.1% to date (from the $123.25 close on Jun 9, 2026).

NUVL Nuvalent, Inc.

$123.43 +22.40% year to date

Daily close · Jun 18, 2026

Key Points

Wells Fargo analyst Eva Fortea Verdejo lowered the rating for Nuvalent (NUVL) from its previous status to Hold on June 9, 2026, setting a new price target of $124.00.
Wells Fargo's $124 price target implies 0.61% upside from Nuvalent, Inc.'s ($NUVL) current $123.25 share price.
Nuvalent shares were trading at $123.25 on Sunday, hovering just below their 52-week high of $123.99 and well above the 200-day moving average of $105.26.
The broader analyst consensus for Nuvalent is currently a Hold, with nine analysts providing opinions and a mean price target that matches the recent $124.00 valuation.

Get $NUVL trade alerts by text

We text you when insiders, Congress or big funds trade $NUVL. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Nuvalent, Inc. alert may contain errors. Disclosures

Wells Fargo Adjusts Outlook on Nuvalent

Wells Fargo analyst Eva Fortea Verdejo lowered the rating on Nuvalent, Inc. (NUVL) to Hold on June 9, 2026. Along with the downgrade, the firm set a price target of $124.00 for the Nasdaq-listed biotechnology company. This move suggests a more neutral stance on the stock's immediate potential compared to previous expectations, especially as the company's share price has climbed significantly over the past year.

Wall Street Sentiment on Nuvalent

The call from Wells Fargo aligns closely with recent moves from other major firms. On June 24, 2026, Bernstein also downgraded the stock to a Market Perform rating, which is similar to a Hold. Bernstein notably cut its price target to $124.00 from a much higher previous target of $172.00. Currently, nine analysts follow the company, resulting in a consensus recommendation of Hold and a mean price target of $124.00. This uniform pricing among analysts suggests Wall Street sees the stock as fairly valued at its current levels.

Nuvalent Stock Performance Near Peak Levels

Nuvalent shares were trading at $123.25 on Sunday, placing the stock very close to its 52-week high of $123.99. The stock has shown steady momentum recently, trading above its 50-day moving average of $114.66 and significantly higher than its 200-day moving average of $105.26. While the stock has climbed far from its 52-week low of $71.13, the new $124.00 price target implies very little room for further growth in the near term according to these analysts.

12-month forecast

$NUVL price target

Nuvalent, Inc. daily closes and this analyst's $124 target. Not advice.

Financial Health and Clinical Progress

Nuvalent is a clinical-stage biopharmaceutical company focused on creating precise therapies for cancer patients. Based in Cambridge, Massachusetts, the firm is currently testing several lead candidates, including Zidesamtinib and Neladalkib, which target specific resistance challenges in non-small cell lung cancer. Because the company is still in the clinical trial phase and has not yet brought a drug to market, it is not currently profitable. It reported a loss of $6.06 per share and has no meaningful P/E ratio. However, the company maintains a strong liquidity position with a current ratio of 16.14, which measures its ability to cover short-term obligations.

What to Watch at Nuvalent, Inc.

Investors should keep an eye on upcoming clinical trial data for NVL-520 and NVL-655, as progress in the Phase 2 portions of these trials often drives volatility for clinical-stage biotech stocks. The alignment of price targets at $124.00 across different firms suggests that any major move above that level may require a new positive catalyst from the company's pipeline. As with all analyst ratings, these views are opinions at a specific point in time and do not guarantee future stock performance.